Karyopharm Therapeutics’ (KPTI) Buy Rating Reaffirmed at Royal Bank Of Canada
Royal Bank Of Canada restated their buy rating on shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in a research report released on Friday. The firm currently has a $15.00 price target on the stock.
A number of other equities research analysts have also recently commented on the stock. Zacks Investment Research upgraded shares of Karyopharm Therapeutics from a hold rating to a buy rating and set a $11.00 price target for the company in a report on Thursday, July 6th. ValuEngine cut shares of Karyopharm Therapeutics from a hold rating to a sell rating in a report on Thursday, August 31st. Jefferies Group LLC restated a buy rating and issued a $16.00 price target on shares of Karyopharm Therapeutics in a report on Friday, July 14th. Cantor Fitzgerald set a $18.00 price target on shares of Karyopharm Therapeutics and gave the stock a buy rating in a report on Thursday, October 12th. Finally, BidaskClub upgraded shares of Karyopharm Therapeutics from a sell rating to a hold rating in a report on Friday, August 25th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. Karyopharm Therapeutics presently has an average rating of Buy and a consensus target price of $15.50.
Karyopharm Therapeutics (KPTI) traded up $0.87 on Friday, hitting $11.23. 2,269,911 shares of the stock traded hands, compared to its average volume of 175,660. Karyopharm Therapeutics has a 52 week low of $6.27 and a 52 week high of $14.63.
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Thursday, November 2nd. The company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 75.03% and a negative net margin of 67,267.47%. research analysts anticipate that Karyopharm Therapeutics will post -2.65 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece was reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/karyopharm-therapeutics-kpti-buy-rating-reaffirmed-at-royal-bank-of-canada/1678828.html.
In other Karyopharm Therapeutics news, Director Mansoor Raza Mirza sold 2,882 shares of the firm’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $11.00, for a total value of $31,702.00. Following the transaction, the director now directly owns 2,882 shares of the company’s stock, valued at $31,702. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 10,695 shares of company stock worth $118,950 over the last ninety days. Insiders own 14.71% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the business. Palo Alto Investors LLC lifted its stake in shares of Karyopharm Therapeutics by 1.8% in the second quarter. Palo Alto Investors LLC now owns 3,467,575 shares of the company’s stock valued at $31,382,000 after buying an additional 61,100 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Karyopharm Therapeutics by 31.1% in the second quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock valued at $14,675,000 after buying an additional 384,658 shares in the last quarter. Tekla Capital Management LLC lifted its stake in shares of Karyopharm Therapeutics by 25.0% in the second quarter. Tekla Capital Management LLC now owns 756,679 shares of the company’s stock valued at $6,848,000 after buying an additional 151,455 shares in the last quarter. State Street Corp lifted its stake in shares of Karyopharm Therapeutics by 10.1% in the second quarter. State Street Corp now owns 511,920 shares of the company’s stock valued at $4,631,000 after buying an additional 47,127 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its stake in shares of Karyopharm Therapeutics by 16.4% in the third quarter. Candriam Luxembourg S.C.A. now owns 510,000 shares of the company’s stock valued at $5,600,000 after buying an additional 72,000 shares in the last quarter. 59.10% of the stock is currently owned by hedge funds and other institutional investors.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.